“…15,16 Interest in ORL-1 has resulted in an increase of publications in scientific and patent literature on related antagonists. 17,18 A decade ago, we identified a series of potent and selective non-peptide ORL-1 antagonists exemplified by J-113397 possessing two stereogenic centers on the piperidine ring ( Fig. 1).…”